Valuation: argenx SE

Capitalization 29.41B 34.37B 27.37B 25.48B 47.04B 2,949B 52.23B 329B 125B 1,381B 129B 126B 5,067B P/E ratio 2025 *
49.2x
P/E ratio 2026 * 27.7x
Enterprise value 26.47B 30.94B 24.64B 22.94B 42.35B 2,655B 47.02B 296B 113B 1,243B 116B 114B 4,562B EV / Sales 2025 *
8.36x
EV / Sales 2026 * 6.18x
Free-Float
99.23%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.01%
1 week+4.37%
Current month+2.28%
1 month-5.41%
3 months-1.58%
6 months-25.39%
Current year-19.92%
More quotes
1 week 456.7
Extreme 456.7
486.4
1 month 456.6
Extreme 456.6
509.8
Current year 456.6
Extreme 456.6
658
1 year 419.8
Extreme 419.8
658
3 years 271
Extreme 271
658
5 years 180.1
Extreme 180.1
658
10 years 8.46
Extreme 8.46
658
More quotes
Manager TitleAgeSince
Chief Executive Officer 53 2008-07-14
Director of Finance/CFO 55 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Director/Board Member 53 2014-06-30
Chairman 67 2008-10-14
Director/Board Member 75 2015-05-12
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.01%+4.37%+11.64%+37.92% 34.72B
-0.90%+2.63%+38.86%-33.64% 28.05B
+9.99%+9.09%+105.51%-29.99% 28B
-3.40%+1.83%+201.57%+2,350.98% 19.22B
+1.57%+0.39%+34.31%+295.89% 18.36B
-1.18%+6.66%-21.93%-44.75% 13.43B
+3.70%+3.29%+150.00%-66.69% 13.32B
+4.52%+6.69%+203.08%+361.10% 12.38B
-0.69%-2.80%+103.45%+103.82% 12.32B
+1.25%-2.69%+156.22% - 9.78B
Average +1.38%+4.70%+98.27%+330.51% 18.96B
Weighted average by Cap. +1.46%+5.14%+84.25%+302.62%
See all sector performances

Financials

2025 *2026 *
Net sales 3.17B 3.7B 2.95B 2.74B 5.07B 318B 5.62B 35.4B 13.48B 149B 13.88B 13.59B 546B 4.1B 4.8B 3.82B 3.56B 6.57B 412B 7.29B 45.88B 17.48B 193B 17.99B 17.62B 707B
Net income 714M 835M 665M 619M 1.14B 71.63B 1.27B 7.98B 3.04B 33.54B 3.13B 3.07B 123B 1.16B 1.36B 1.08B 1.01B 1.86B 116B 2.06B 12.97B 4.94B 54.5B 5.09B 4.98B 200B
Net Debt -2.93B -3.43B -2.73B -2.54B -4.69B -294B -5.21B -32.78B -12.48B -138B -12.85B -12.59B -505B -4.05B -4.73B -3.77B -3.51B -6.48B -406B -7.19B -45.25B -17.23B -190B -17.74B -17.37B -697B
More financial data * Estimated data
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,599
More about the company
Date Price Change Volume
25-07-11 480.50 -1.01% 73,198
25-07-10 485.40 +4.39% 76,016
25-07-09 465.00 +0.19% 106,140
25-07-08 464.10 -0.39% 80,099
25-07-07 465.90 -0.26% 56,141

Real-time Euronext Bruxelles, July 11, 2025 at 11:55 am EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
480.50EUR
Average target price
664.70EUR
Spread / Average Target
+38.34%
Consensus

Quarterly revenue - Rate of surprise